ZimVie (ZIMV) Competitors $18.98 +0.01 (+0.03%) Closing price 03:58 PM EasternExtended Trading$18.98 +0.01 (+0.05%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZIMV vs. LQDA, LMAT, PRCT, AORT, ENOV, NVCR, CDRE, CNMD, PLSE, and KMTSShould you be buying ZimVie stock or one of its competitors? The main competitors of ZimVie include Liquidia Technologies (LQDA), LeMaitre Vascular (LMAT), PROCEPT BioRobotics (PRCT), Artivion (AORT), Enovis (ENOV), NovoCure (NVCR), Cadre (CDRE), CONMED (CNMD), Pulse Biosciences (PLSE), and Kestra Medical Technologies (KMTS). These companies are all part of the "medical equipment" industry. ZimVie vs. Its Competitors Liquidia Technologies LeMaitre Vascular PROCEPT BioRobotics Artivion Enovis NovoCure Cadre CONMED Pulse Biosciences Kestra Medical Technologies ZimVie (NASDAQ:ZIMV) and Liquidia Technologies (NASDAQ:LQDA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends. Is ZIMV or LQDA more profitable? ZimVie has a net margin of -4.39% compared to Liquidia Technologies' net margin of -732.17%. ZimVie's return on equity of 6.37% beat Liquidia Technologies' return on equity.Company Net Margins Return on Equity Return on Assets ZimVie-4.39% 6.37% 3.34% Liquidia Technologies -732.17%-232.96%-60.81% Which has higher earnings and valuation, ZIMV or LQDA? ZimVie has higher revenue and earnings than Liquidia Technologies. ZimVie is trading at a lower price-to-earnings ratio than Liquidia Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZimVie$449.75M1.19-$25.83M-$0.70-27.11Liquidia Technologies$14M139.80-$130.39M-$1.70-13.37 Which has more risk & volatility, ZIMV or LQDA? ZimVie has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Liquidia Technologies has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Do analysts recommend ZIMV or LQDA? ZimVie currently has a consensus price target of $17.75, suggesting a potential downside of 6.46%. Liquidia Technologies has a consensus price target of $32.38, suggesting a potential upside of 42.40%. Given Liquidia Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Liquidia Technologies is more favorable than ZimVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZimVie 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80Liquidia Technologies 2 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.70 Do insiders and institutionals hold more shares of ZIMV or LQDA? 95.6% of ZimVie shares are owned by institutional investors. Comparatively, 64.5% of Liquidia Technologies shares are owned by institutional investors. 5.4% of ZimVie shares are owned by company insiders. Comparatively, 30.1% of Liquidia Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to ZIMV or LQDA? In the previous week, ZimVie had 3 more articles in the media than Liquidia Technologies. MarketBeat recorded 9 mentions for ZimVie and 6 mentions for Liquidia Technologies. ZimVie's average media sentiment score of 0.54 beat Liquidia Technologies' score of 0.34 indicating that ZimVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ZimVie 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia Technologies 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryZimVie beats Liquidia Technologies on 10 of the 17 factors compared between the two stocks. Get ZimVie News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIMV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZIMV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIMV vs. The Competition Export to ExcelMetricZimVieMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$535.29M$10.45B$6.04B$10.45BDividend YieldN/A1.90%5.73%4.82%P/E Ratio-27.1121.0085.1427.26Price / Sales1.1930.83590.92134.18Price / Cash10.2125.5625.7730.18Price / Book1.373.4412.666.76Net Income-$25.83M$210.63M$3.32B$276.50M7 Day Performance0.29%-1.54%0.44%0.88%1 Month Performance0.56%0.59%9.35%8.17%1 Year Performance20.02%-6.68%79.07%43.52% ZimVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIMVZimVie1.1519 of 5 stars$18.98+0.0%$17.75-6.5%+18.6%$535.29M$449.75M-27.111,770LQDALiquidia Technologies3.2723 of 5 stars$23.24+1.6%$32.38+39.3%+114.4%$2.01B$19.32M-13.7450LMATLeMaitre Vascular3.7625 of 5 stars$86.91-0.7%$97.60+12.3%-5.8%$1.97B$219.86M42.19490PRCTPROCEPT BioRobotics2.9813 of 5 stars$35.34+0.3%$70.00+98.1%-54.0%$1.97B$224.50M-22.79430AORTArtivion3.1887 of 5 stars$40.80+0.1%$43.13+5.7%+56.8%$1.92B$388.54M-97.141,600News CoverageENOVEnovis3.651 of 5 stars$31.49+0.7%$51.00+62.0%-26.0%$1.80B$2.11B-2.217,367Gap DownNVCRNovoCure4.098 of 5 stars$14.52+0.1%$27.50+89.5%-15.9%$1.62B$630.16M-9.311,488Gap DownCDRECadre2.512 of 5 stars$37.41-0.3%$31.50-15.8%-3.0%$1.52B$567.56M39.852,284Analyst DowngradeCNMDCONMED4.5592 of 5 stars$46.64+0.4%$59.80+28.2%-32.0%$1.45B$1.33B13.243,900PLSEPulse Biosciences3.7837 of 5 stars$19.63+0.9%$22.00+12.1%+1.5%$1.33B$700K-18.82140KMTSKestra Medical Technologies1.7706 of 5 stars$25.66+2.5%$27.33+6.5%N/A$1.32B$59.81M0.00300 Related Companies and Tools Related Companies Liquidia Technologies Competitors LeMaitre Vascular Competitors PROCEPT BioRobotics Competitors Artivion Competitors Enovis Competitors NovoCure Competitors Cadre Competitors CONMED Competitors Pulse Biosciences Competitors Kestra Medical Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIMV) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhy Wall Street is piling into the “Debasement Trade”Wall Street is piling into what insiders are calling the “Debasement Trade” — and according to former Goldman ...Stansberry Research | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZimVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZimVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
